Early-to-market DTx products hewed closely to the same path to market that pharmaceutical therapies use. This model either relies heavily on a pharmaceutical partner's salesforce or requires the DTx company to build their own. So, is a partnership the better option? 

What are the main requirements from both parties before partnering up? Which are the successful DTx partnerships so far? What are the lessons learned from things that worked or didn’t work? What are the main KPIs to measure the success of a DTx partnership? In this meeting we will dive into the challenges to make DTx partnerships thrive, current partnerships and the reason why DTx companies, Pharma and Medtech should or shouldn’t look for these collaborations.